Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040

1 Apr 2005

Abstract excerpt

PD184352/CI-1040 is a potent and selective MEK1/2 inhibitor that represents the first MEK-targeted agent to enter clinical trials. Here, we report the development and molecular characterization of CI-1040 resistance in the murine colon 26 (C26) carcinoma cell line. The growth rate of the resistant line (C26/CI-1040r) in the presence of 2 microM CI-1040 is comparable to that of parental C26 cells in the absence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15967111
DOI: 10.1593/neo.04532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040PMID 15967111Read ↗

Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancerSemantic proximity Read ↗

Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.Semantic proximity Read ↗

Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status.Semantic proximity Read ↗

The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors.Semantic proximity Read ↗

Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon AdenocarcinomaSemantic proximity Read ↗

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.Semantic proximity Read ↗

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer modelsSemantic proximity Read ↗

Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer CellsSemantic proximity Read ↗

Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.Semantic proximity Read ↗

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.Semantic proximity Read ↗

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.Semantic proximity Read ↗

Protein Kinase Cα Protects Against Multidrug Resistance in Human Colon Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.